Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Cancer. 2012 May 15;118(10):2752-62. doi: 10.1002/cncr.26564. Epub 2011 Oct 11.
Previous intracranial germinoma (IG) studies have investigated the effect of different radiotherapy (RT) volumes and the necessity for adjunctive chemotherapy, but there is currently no consensus on the best treatment for this tumor.
From January 1989 to December 2009, 80 IG patients (≤20 years old) were treated with various RT regimens. Of them, 14 patients had craniospinal irradiation (CSI) + primary boost (PB); 8 patients had whole-brain irradiation (WBI) + PB; 31 patients had whole ventricular irradiation (WVI) + PB; and 27 patients had focal RT only. Twenty-nine patients (36.2%) also received systemic chemotherapy (CHT). Survival was estimated by the Kaplan-Meier method and variables affecting survival were analyzed by the Cox proportional hazard model.
Eleven patients (13.8%) developed local recurrence or dissemination after treatment, and 10 of these patients were in the focal RT group. The 5-year relapse-free survival (RFS) for the CSI, WBI, WVI, and focal RT patients were 100%, 85.7%, 100%, and 84.6%, respectively (P = .001). The 5-year overall survival (OS) for CSI, WBI, WVI, and focal RT patients was 100%, 83.3%, 100%, and 87.9%, respectively (P = .125). Focal irradiation (P = .02) and initial use of CHT (P = .021) were negatively associated with RFS.
Focal RT plus CHT were associated with inferior control of IG and a higher incidence of CHT-related toxicities. Adjustment of the radiation volume to the whole ventricular system without CHT is sufficient for treatment of nondisseminated IGs, even with lower primary RT doses (<36 Gy).
之前的颅内生殖细胞瘤(IG)研究已经探讨了不同放射治疗(RT)体积的效果和辅助化疗的必要性,但目前对于这种肿瘤的最佳治疗方法尚无共识。
1989 年 1 月至 2009 年 12 月,80 例 IG 患者(≤20 岁)接受了不同的 RT 方案治疗。其中,14 例患者接受了颅脊髓照射(CSI)+原发灶强化(PB);8 例患者接受了全脑照射(WBI)+PB;31 例患者接受了全脑室照射(WVI)+PB;27 例患者仅接受局部 RT。29 例(36.2%)患者还接受了全身化疗(CHT)。采用 Kaplan-Meier 法估计生存率,采用 Cox 比例风险模型分析影响生存的因素。
11 例(13.8%)患者治疗后出现局部复发或播散,其中 10 例患者在局部 RT 组。CSI、WBI、WVI 和局部 RT 患者的 5 年无复发生存率(RFS)分别为 100%、85.7%、100%和 84.6%(P=.001)。CSI、WBI、WVI 和局部 RT 患者的 5 年总生存率(OS)分别为 100%、83.3%、100%和 87.9%(P=.125)。局部照射(P=.02)和初始使用 CHT(P=.021)与 RFS 呈负相关。
局部 RT 加 CHT 与 IG 控制不良和 CHT 相关毒性增加有关。不进行 CHT 的全脑室系统放射治疗体积调整对于非播散性 IG 是足够的,即使初始 RT 剂量较低(<36 Gy)。